Phytomedicines developer MGC Pharmaceuticals Ltd (ASX:MXC) is cosponsoring a Clinical Study into the influence of MGC Pharma’s proprietary supplement, ArtemiC Support, in patients with Long COVID Syndrome.
Long COVID or post-acute COVID syndrome, refers to the ongoing health problems that people can experience four or more weeks after first being infected with SARS-COV-2, the virus responsible for COVID-19.
This condition is believed to affect 10–35% of all COVID-19 patients.
The Study is being sponsored by MGC Pharma’s distribution partner, Swiss PharmaCan AG (SPC) and is cosponsored by MGC Pharma and Glow LifeTech Ltd.
The study received Ethics Committee approval from Spanish Foundation, IDIAP Gordi Gol, on December 9, 2021 and is now underway, with 50 of the targeted 150 patients enrolled. In total, 150 patients suffering from Long COVID Syndrome will be enrolled into the Spanish study.
Patients will administer ArtemiC Support for six weeks under supervision of their doctor, with their progress being measured using a Post-COVID Functional Scale (PCFS)3 and a 10-point Likert scale 1, 2, 3 and 6 weeks after treatment initiation.
The symptoms measured include:
1. Dyspnea – shortness of breath
2. Asthenia – abnormal physical weakness or lack of energy
3. Anosmia – loss of senses of smell
4. Ageusia – loss of sense of taste
5. Cough
6. Headache
7. Mental confusion.
The study has commenced and is expected to conclude in February 2022, subject to enrolment targets being achieved, and results published in Q2 2022.
Dependent on the findings, it is anticipated that a further randomised, double-blind, placebo-controlled study, to get full information on efficacy and safety of ArtemiC Support in patients suffering from Long COVID Syndrome will follow.
ArtemiC Support is the second product in the company’s ArtemiC product range to progress to the Clinical Trial phase to determine their safety and efficacy against SARS-COV-2 related diseases.
In 2020 MGC Pharma undertook a Phase II Clinical Trial for ArtemiCTM to determine its safety and efficacy in patients diagnosed with moderate COVID-19, and to evaluate their recovery rates.
